AOL Web Search

There have been reports of a “rebound” of COVID-19 symptoms in some people within 2 to 8 days after completing the five-day course of Paxlovid; in those cases, some have tested positive again but have no symptoms; others have a recurrence of symptoms.

When Paxlovid is stopped, the virus starts replicating again. It’s possible that Paxlovid may need to be given for a longer period of time – maybe seven or 10 days instead of five days. Those ...

A June preprint study shows 3.53% of people may experience a rebound within 7 days of taking Paxlovid, but the rate of symptomatic rebound is only 2.31%. After 30 days, the chance of a COVID rebound after Paxlovid increases slightly to 5.4%. Some researchers suspect more people may be rebounding after Paxlovid than we think.

Nirmatrelvir/ritonavir, sold under the brand name Paxlovid, is a co-packaged medication used as a treatment for COVID‑19. It contains the antiviral medications nirmatrelvir and ritonavir and was developed by Pfizer.

A study that reveals how the virus mutates to escape Paxlovid could now help chemists design better drugs that are more difficult for SARS-CoV-2 to sidestep. The study, led by researchers at Columbia University and several universities in China, was published Sept. 11 in Nature.

Escape mutations in SARS-CoV-2 In the study, Iketani and colleagues looked at how mutations allow the virus to evade nirmatrelvir. Images of the drug when bound to its viral target, Mpro, revealed...